Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance.


Journal Article

Darunavir (TMC114) is a second-generation, sulfonamide, nonpeptidic protease inhibitor (PI) with a unique, flexible, 3-dimensional structure that contributes to it high potency and slow selection of resistant virus. Darunavir has to be coadministered with low-dose ritonavir and food to optimize its pharmacokinetics. Ritonavir-boosted darunavir is effective in many heavily pretreated patients, including those with multiple PI resistance mutations. In vitro, the coexistence of numerous PI mutations was required for its virological potency to be significantly reduced. Preliminary findings suggest that it is active against some tipranavir-resistant strains.

Full Text

Cited Authors

  • Taiwo, BO; Hicks, CB

Published Date

  • March 2007

Published In

Volume / Issue

  • 17 / 3

Start / End Page

  • 151 - 161

PubMed ID

  • 17396332

Pubmed Central ID

  • 17396332

International Standard Serial Number (ISSN)

  • 1053-0894


  • eng